Delving into the Latest Updates on Tot Biopharm Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Respiratory Diseases

Monoclonal antibody

Antibody drug conjugate (ADC)

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Endocrinology and Metabolic Disease	2
Immune System Diseases	1
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	3
Antibody drug conjugate (ADC)	3
Biosimilar	2
Recombinant protein	2

Top 5 Target	Count

TOP1 x Trop-2	2
VEGF(Vascular endothelial growth factor)	1
HER2(Receptor tyrosine-protein kinase erbB-2)	1
EGFR(Epidermal growth factor receptor erbB1)	1
Hyaluronic acid	1

[Translation] An open-label, randomized, multicenter phase III study evaluating ESG401 versus investigator-selected chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer who have received at least one line of systemic chemotherapy

主要目的：对比ESG401与研究者所选化疗方案由独立中心影像评估的无疾病进展时间（PFS）。次要目的：对比ESG401与研究者所选化疗方案由研究者评估的无疾病进展（PFS），总生存期（OS），客观缓解率（ORR），临床获益率（CBR），缓解持续时间（DOR）。

[Translation]

Primary objective: To compare the progression-free time (PFS) assessed by independent central imaging between ESG401 and the chemotherapy regimen selected by the investigator. Secondary objective: To compare the progression-free time (PFS), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR) assessed by the investigator between ESG401 and the chemotherapy regimen selected by the investigator.

Start Date25 Jun 2024

Sponsor / Collaborator

Tot Biopharm Co. Ltd.

[+1]

NCT05461339 / RecruitingPhase 3

A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients

This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients. The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).

Start Date28 Jun 2022

Sponsor / Collaborator

Tot Biopharm Co. Ltd.

[+1]

NCT05427305 / CompletedPhase 3

Bevacizumab Biosimilar Candidate TAB008 Compared to Avastin® in Patients With Locally Advanced, Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Multicenter Study

In this randomized, double-blind, multicenter, phase III similarity study, treatment naive, EGFR wild-type, locally advanced, metastatic, or recurrent non-squamous, non-small cell, lung cancer (ns-NSCLC) patients were enrolled and randomized (1:1) into TAB008 or Bevacizumab-EU groups. Patients received TAB008 or bevacizumab-EU 15 mg/kg intravenously plus paclitaxel/carboplatin for 4-6 cycles followed by TAB008 or bevacizumab-EU 7.5 mg/kg until disease progression, unacceptable toxicity or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints compared disease control rate (DCR) Within 6 cycles, duration of response (DoR), progression free survival (PFS), a year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and steady state pharmacokinetics.

Start Date20 Oct 2017

Sponsor / Collaborator

Tot Biopharm Co. Ltd.

100 Clinical Results associated with Tot Biopharm Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Tot Biopharm Co. Ltd.

Login to view more data

2

Literatures (Medical) associated with Tot Biopharm Co. Ltd.

01 Jan 2021·Journal of CancerQ3 · MEDICINE

MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/β-Catenin Signal Pathway

Q3 · MEDICINE

ArticleOA

Author: Chu, Lei ; Chen, Zhenshi ; Wang, Lihui ; Zhang, Shaoru ; Lian, Xiaoning ; Wu, Weidong ; Chen, Tonglei

Objective: To investigate the high expression of MUC15 in promoting proliferation, migration and invasion in osteosarcoma (OS) cell and its potential mechanism. Methods: The expressions of MUC15 in OS patients were analyzed from GEO Datasets, tumor cell lines and clinical samples. The roles of MUC15 in OS were explored by CCK-8, flow cytometry, transwell and western blot assay, respectively. Results: MUC15 was highly expressed in osteosarcoma, and there was a significant negative correlation between MUC15 and the prognosis. Knockdown of MUC15 in HOS and U-2OS could promote tumor cell apoptosis, down-regulate the expression of MMP2/9, reduce the epithelial interstitial transition and silence the Wnt/b-Catenin signal pathway. Conclusion: The high-expression of MUC15 promotes the proliferation, migration and invasion of osteosarcoma through anti-apoptosis, increasing the invasive ability by epithelial interstitial transition, and activating the Wnt/b-Catenin signal pathway.

16 Aug 2018·Current Drug DeliveryQ4 · MEDICINE

Protective Effects of Magnesium Sulfate on Radiation Induced Brain Injury in Rats

Q4 · MEDICINE

Article

Author: Wang, Li L ; Tu, Yu ; Chen, Na ; Zhang, Meng ; Zhou, Ju Y ; Xu, Rui J ; Feng, Shi C

OBJECTIVESThe effect of magnesium sulfate on brain tissue of SD rats irradiated by 6MeV electron was investigated.METHODSSD rats were divided into three groups: control group, irradiation (IR group) and irradiation treated with magnesium sulfate (IR+M group). After being anesthetized, the whole brains of IR group and IR+M group were exposed to 6 MeV electron radiation. IR+M group was i.p. injected with 10% magnesium sulfate (400 mg/kg) one day before radiation and three days and five days after radiation. And on the 1st, 3rd, 7th and 14th day after radiation, SD rats were euthanatized to take brain tissue for the detection of calcium, redox status and cell apoptosis, as well as the expression of NF-κB and ICAM-1.RESULTSThe results indicated that magnesium treatment may alleviate the elevation of calcium and enhance redox status through increasing the activities of superoxide dimutase (SOD) and myeloperodase (MPO), and decreasing the concentration of malondialdehyde (MDA). Tunnel and immunohistochemistry assay suggested that treatment with magnesium decreased the apoptosis rate of brain cells and the expressions of caspase-3, respectively. Decline of the expression of NF-κB and ICAM-1 protein was observed after the treatment of magnesium.CONCLUSIONAll the results demonstrated that magnesium may elicit protective effect against radiationinduced brain injury by reducing calcium overload, improving redox and inhibiting cell apoptosis. Moreover, magnesium significantly down-regulated the protein or mRNA levels of NF-κB and ICAM- 1. The findings may provide references for the application of magnesium in clinic for brain injury induced by radiation.

100 Deals associated with Tot Biopharm Co. Ltd.

Login to view more data

100 Translational Medicine associated with Tot Biopharm Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

3

Preclinical

Phase 3 Clinical

2

1

NDA/BLA

Approved

1

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Bevacizumab biosimilar (Tot Biopharm) ( VEGF-A )	Non-Small Cell Lung Cancer More	Approved
Becotatug vedotin ( EGFR )	Nasopharyngeal Carcinoma More	NDA/BLA
ESG-401 ( TOP1 x Trop-2 )	Hormone receptor positive HER2 negative breast cancer More	Phase 3
TAB014 ( VEGF )	Wet age-related macular degeneration More	Phase 3
Trastuzumab Biosimilar(TOT Biopharm) ( HER2 )	Mantle-Cell Lymphoma More	Preclinical